12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tivantinib: Additional Phase II data

Additional data from a double-blind, international Phase II trial in 107 patients with unresectable HCC who failed 1 prior systemic therapy showed that twice-daily oral tivantinib missed the secondary endpoint of median PFS vs. placebo (1.7 vs. 1.5 months, p=0.06). In a subgroup of 37 patients whose tumors had high c-Met expression, tivantinib led to...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >